Zynex, Inc. specializes in non-invasive pain management and patient monitoring, with promising advancements like the NiCO pulse oximeter targeting accurate readings for diverse skin tones. Despite ...

Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company’s possible violations of ...

Shares of Zynex fell after the it said that the health insurance company Tricare--which accounts for as much as 25% of its total revenue--has temporarily suspended payments as it reviews prior claims.

Ladenburg downgraded Zynex (ZYXI) to Neutral from Buy without a price target saying the company continues to adjust operationally amid revenue pressure. Effectively assess a stock's risks and ...

Zynex is cutting 15% of its workforce after health insurance company Tricare temporarily suspended payments. The medical device maker said Tuesday it plans to cut jobs because Tricare has ...

Good afternoon, ladies and gentlemen, and welcome to the Zynex fourth-quarter 2024 earnings conference call. (Operator Instructions) As a reminder, this conference is being recorded. I would now ...

Zynex (NASDAQ:ZYXI – Get Free Report) had its price objective lowered by equities researchers at HC Wainwright from $17.00 to $15.00 in a research note issued on Wednesday,Benzinga reports.

Zynex (ZYXI) delivered earnings and revenue surprises of -122.22% and 14.39%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? Zynex ...

H.C. Wainwright lowered the firm’s price target on Zynex (ZYXI) to $15 from $17 and keeps a Buy rating on the shares. The company reported a top- and bottom-line miss in Q4 due to payor review ...

Good afternoon, ladies and gentlemen, and welcome to the Zynex Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. A question-and-answer session ...